Who is sponsoring NCT03674463?

NCT03674463 is sponsored by Second Affiliated Hospital of Xi'an Jiaotong University.

What drugs are being tested in NCT03674463?

Interventions in NCT03674463: LCAR-B4822M CAR-T Cell Immunotherapy.

What condition does NCT03674463 study?

NCT03674463 studies Refractory or Relapsed Multiple Myeloma.

Is NCT03674463 still recruiting?

NCT03674463 is currently status unknown. Last updated 14 December 2018.

Last reviewed 2018-12-14 · How we verify

NCT03674463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Status unknown Phase 1 Last updated 14 December 2018

What this trial tests

Phase 1 trial testing LCAR-B4822M CAR-T Cell Immunotherapy in Refractory or Relapsed Multiple Myeloma in 10 participants. Status unknown.

Timeline

26 July 2018

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Second Affiliated Hospital of Xi'an Jiaotong University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	26 July 2018
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

LCAR-B4822M CAR-T Cell Immunotherapy — full drug profile →

Conditions studied

Refractory or Relapsed Multiple Myeloma — all drugs for Refractory or Relapsed Multiple Myeloma →

Sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Who can join

Adults 18 to 73, any sex, with Refractory or Relapsed Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of LCAR-B4822M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M, Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al · · 2024 · cited 109× · PMID 38438559 · DOI 10.1038/s41417-024-00750-2
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
Nanobodies: Robust miniprotein binders in biomedicine.
Yong Joon Kim J, Sang Z, Xiang Y, Shen Z, et al · · 2023 · cited 46× · PMID 36754285 · DOI 10.1016/j.addr.2023.114726

Verify or expand the search:

Other recruiting trials for Refractory or Relapsed Multiple Myeloma

Currently open trials in the same condition.

NCT06952478 — A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With · Phase 3 · recruiting

Other Second Affiliated Hospital of Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07160361 — Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB · Phase 4 · not yet recruiting
NCT07346456 — Comparison of IOL Formulas in Eyes With PCE≥15µm · completed
NCT06998589 — Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of P · NA · completed
NCT07305675 — Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment · NA · completed
NCT06791005 — A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03674463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Xi'an Jiaotong University
Last refreshed: 14 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03674463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing